Stocks in play: Greenbrook TMS Inc.
And Neuronetics, Inc, a commercial stage medical technology company with a strategic vision of transforming the lives of patients whenever and wherever they need it with the best neurohealth therapies in the world, today announced they have entered into a five-year commercial agreement which provides for a stronger collaborative relationship between the parties. Greenbrook TMS Inc. shares T.GTMS are trading down $0.03 at $3.44.
Read:
Merger Arbitrage Opportunities Abound as Early 2022 M&A Activities Give Premium Prices
Tech Innovation and Joint Efforts Needed for US to Achieve Energy Independence Once Again
Increasing Domestic Oil Supplies Will Require Innovation and Group Efforts
The M&A Flurry That Started in 2021 Isn’t Even Close to Done, According to Analysts
Market Response to Oil and Gas Stocks Proving Energy Industry Can Still be ESG Friendly